Many here may think I am very negative about AHZ - not the case with their products but I think there marketing and sales strategy is wrong.
They are not a gorilla in the health landscape - they are hampered by cash constraints .
My thoughts is that they need to do collaborations with the major players.
Keep the ADAPT tech tightly held but licence it to those majors in the different fields - coronary, vascular etc
Clip the ticket as others pay for the development sales and marketing
Ditch their sales team - too many products to market not enough feet on the ground in the surgeons faces .
This way sales will increase . I just can't see they are going to get volume .
Volume is what it is all about . Profits will increase . Costs reduce .
Bit like writing a book and trying to publish and sell it yourself . The author gets a royalty the publisher takes the risk.
- Forums
- ASX - By Stock
- AVR
- Ann: Update on Admedus shaped patch product franchise
Ann: Update on Admedus shaped patch product franchise, page-26
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.68 |
Change
0.680(4.53%) |
Mkt cap ! $331.4M |
Open | High | Low | Value | Volume |
$14.90 | $15.75 | $14.85 | $431.9K | 28.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $15.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.95 | 300 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 15.210 |
1 | 100 | 15.020 |
1 | 332 | 15.000 |
1 | 500 | 14.770 |
1 | 1000 | 14.450 |
Price($) | Vol. | No. |
---|---|---|
15.950 | 300 | 1 |
16.000 | 250 | 1 |
16.030 | 999 | 1 |
16.500 | 971 | 1 |
17.500 | 511 | 2 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |